Phosphorylated TDP-43 (pTDP-43) is a pathologic lesion characteristic of some degenerative diseases as ALS and frontotemporal dementia (FTD), but also inclusion body myositis [13–16] The only approved treatment, riluzole, is only moderately effective [17]. This evidence concerns the gene TARDBP and frontotemporal dementia.